Johnson & Johnson vaccine: Quality issue at Baltimore plant delays some of the J&J supply
CNNCNN — Drugmaker Johnson & Johnson said Wednesday it had found a quality problem at a Baltimore plant helping manufacture its single-dose coronavirus vaccine under contract. Johnson & Johnson said in a statement to CNN Wednesday that the quality control process at the plant identified “one batch” of drug substance that did not meet quality standards. On Wednesday evening, Biden administration officials stressed that the quality issue with Johnson & Johnson’s Baltimore manufacturing plant won’t affect the president’s ultimate goal of making vaccines available to all Americans by May. Last week, the Biden administration expressed some doubts the company could meet its self-imposed deadline, but by Friday, the administration seemed more confident that J&J would meet its goal, as White House coronavirus coordinator Jeffrey Zients said, “they appear on track to meet that goal with at least 11 million doses delivered next week.” The FDA authorized J&J’s single-dose Covid-19 vaccine in late February, but the company had struggled to ramp up production and failed to meet earlier production timelines that had been laid out in its contract with the federal government.